Fitzgrald

46

RAW SEQUENCE LISTING PATENT APPLICATION US/09/016,159

DATE: 01/27/1999 TIME: 15:14:04

INPUT SET: S30362.raw

This Raw Listing contains the General Information Section and up to the first 5 pages.

1 2		SEQUENCE LISTING ENTERED
3	(1) Ge:	neral Information:
4	(1)	
5 6	(i) .	APPLICANT: Lee, Jong Y.
7 8 9	(ii)	TITLE OF INVENTION: PURIFIED HUMAN ERYTHROPOIETIN RECEPTOR PROTEIN FRAGMENT AND ANTIBODIES DERIVED THEREFROM
10 11	(iii) :	NUMBER OF SEQUENCES: 5
12 13 14 15 16 17 18	(iv)	CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Fish & Richardson P.C., P.A. (B) STREET: 60 South Sixth Street, Suite 3300 (C) CITY: Minneapolis (D) STATE: MN (E) COUNTRY: USA (F) ZIP: 55402
20 21 22 23 24 25	(v)	COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM compatible (C) OPERATING SYSTEM: DOS (D) SOFTWARE: FastSEQ for Windows Version 2.0
26 27 28 29	(vi)	CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: 09/016,159 (B) FILING DATE: 30-JAN-1998
30 31 32 33	(vi)	PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: 08/876,227 (B) FILING DATE: 16-JUN-1997
34 35 36 37	(vi)	PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: 08/734,097 (B) FILING DATE: 21-OCT-1996
38 39 40 41	(vi) :	PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: 08/460,525 (B) FILING DATE: 02-JUN-1995
42 43 44 45	(viii) i	ATTORNEY/AGENT INFORMATION: (A) NAME: Ellinger, Mark S. (B) REGISTRATION NUMBER: 34,812 (C) REFERENCE/DOCKET NUMBER: 07004/002003

RAW SEQUENCE LISTING PATENT APPLICATION US/09/016,159

DATE: 01/27/1999 TIME: 15:14:04

INPUT SET: S30362.raw

		1.11 01 521. 5000021.40
47 48 49 50	(ix)	TELECOMMUNICATION INFORMATION: (A) TELEPHONE: 612/335-5070 (B) TELEFAX: 612/288-9696
52 53	(2) INFO	RMATION FOR SEQ ID NO:1:
54 55 56 57 58	(i)	SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear
60 61	(ii)	MOLECULE TYPE: synthetic DNA
62 63	(iii)	HYPOTHETICAL: NO
64 65 66	(iv)	ANTI-SENSE: NO
67 68 69		FEATURE: (A) NAME/KEY: BamH1 linker ar 5' end followed by sequence for aminothrough 29 of the full length human Epor protein. Forward primer for
70 71 72		ID No. 2."
73 74	(xi)	SEQUENCE DESCRIPTION: SEQ ID NO:1:
75 76 77 78	TTGGATCC	GCG CCC CCG CCT A AC 23 Ala Pro Pro Pro 1
79 80	(2) INFO	RMATION FOR SEQ ID NO:2:
81 82 83 84 85	(i)	SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear
87 88	(ii)	MOLECULE TYPE: synthetic DNA
89 90	(iii)	HYPOTHETICAL: NO
91 92 93	(iv)	ANTI-SENSE: NO
94 95		FEATURE: (A) NAME/KEY: EcoR1 linker followed by sequence complementary to
96 97 98	coding se	equence for amino acids 226 through 222 of full length human EpoR Reverse primer for Sequence ID No. 1.

99

RAW SEQUENCE LISTING PATENT APPLICATION US/09/016,159

DATE: 01/27/1999 TIME: 15:14:05

INPUT SET: \$30362.raw

	INPUI SEI: 530362.ra	W
100 101	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:	
102 103	TGAATTCGGG GTCCAGGTCG CT	22
104	(2) INFORMATION FOR SEQ ID NO:3:	
105 106 107 108 109 110	 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear 	
112 113	(ii) MOLECULE TYPE: other nucleic acid	
114 115	(iii) HYPOTHETICAL: NO	
116 117	(iv) ANTI-SENSE: NO	
118 119 120	(vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens	
121 122 123	<pre>(vii) IMMEDIATE SOURCE: (B) CLONE: pGEX-2T, Pharmacia (Mechanicsburg, PA)</pre>	
124 125 126	<pre>(ix) FEATURE: (A) NAME/KEY: Thrombin Cleavage Site in plasmid vector pGEX-2</pre>	т. "
127 128 129 130 131 132	 (x) PUBLICATION INFORMATION: (A) AUTHORS: Smith, D.B. Johnson, K.S. (B) TITLE: Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione-S-transferase (D) VOLUME: 67 	
134 135	(F) PAGES: 31-40 (G) DATE: 1988	
136 137	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:	
138 139 140 141 142	CTG GTT CCG CGT GGA T CC Leu Val Pro Arg Gly 5	18
143 144 145 146 147 148	(2) INFORMATION FOR SEQ ID NO:4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1527 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double	
149 150 151 152	(D) TOPOLOGY: linear (x) PUBLICATION INFORMATION:	

RAW SEQUENCE LISTING PATENT APPLICATION US/09/016,159

DATE: 01/27/1999 TIME: 15:14:05

INPUT	SET:	S30362.	raw
-------	------	---------	-----

														IN	PUT S	ET: S3	30362.raw
153			(A) AU'	THOR	S: W	inke	lmanı	n.,	J. C	., e	t al					
154			(C) JO	URNA	L: B	lood										
155			(D) VO	LUME	: 76											
156			(E) IS	SUE:	1											
157			(F) PA	GES:	24-	30										
158			(G) DA	TE:	1990											
159		(x)	PUB:	LICA	TION	INF	ORMA'	TION	:								
160			(A) AU'	THOR	S: J	ones	, s.:	s., (et a	1.						
161							lood		-								
162			(D) VO	LUME	: 76											
163			(E) IS	SUE:	1											
164			(F) PA	GES:	31-	35										
165			(G	DA'	TE:	1990											
166		(x)					ORMA'	TION	:								
167			(A) AU'	THOR	S: No	oque!	hi, (C.T.	, et	al.						
168							lood	•		•							
169) Vo:													
170) IS													
171							8-25	56									
172				DA'													
173																	
174		(xi)	SEQ	UENC	E DE	SCRI	PTIO	N: SI	EQ I	D NO	:4:						
175																	
176	ATG	GAC	CAC	CTC	GGG	GCG	TCC	CTC	TGG	CCC	CAG	GTC	GGC	TCC	CTT	TGT	48
177								Leu									
178	1	-			5					10					15	-	
179																	
180	CTC	CTG	CTC	GCT	GGG	GCC	GCC	TGG	GCG	CCC	CCG	CCT	AAC	CTC	CCG	GAC	96
181	Leu	Leu	Leu	Ala	Gly	Ala	Ala	Trp	Ala	Pro	Pro	Pro	Asn	Leu	Pro	Asp	
182				20	_				25					30			
183																	
184	CCC	AAG	TTC	GAG	AGC	AAA	GCG	GCC	TTG	CTG	GCG	GCC	CGG	GGG	CCC	GAA	144
185	Pro	Lys	Phe	Glu	Ser	Lys	Ala	Ala	Leu	Leu	Ala	Ala	Arg	Gly	Pro	Glu	
186			35					40					45				
187																	
188	GAG	CTT	CTG	TGC	TTC	ACC	GAG	CGG	TTG	GAG	GAC	TTG	GTG	TGT	TTC	TGG	192
189	Glu	Leu	Leu	Cys	Phe	Thr	Glu	Arg	Leu	Glu	Asp	Leu	Val	Cys	Phe	Trp	
.190		50					55	•				60					
191																	
192	GAG	GAA	GCG	GCG	AGC	GCT	GGG	GTG	GGC	CCG	GGC	AAC	TAC	AGC	TTC	TCC	240
193	Glu	Glu	Ala	Ala	Ser	Ala	Gly	Val	Gly	Pro	Gly	Asn	Tyr	Ser	Phe	Ser	
194	65					70					75					80	
195																	
196	TAC	CAG	CTC	GAG	GAT	GAG	CCA	TGG	AAG	CTG	TGT	CGC	CTG	CAC	CAG	GCT	288
197	Tyr	Gln	Leu	Glu	Asp	Glu	Pro	Trp	Lys	Leu	Cys	Arg	Leu	His	Gln	Ala	
198	•				85			-	-	90	-	_			95		
199																	
200	CCC	ACG	GCT	CGT	GGT	GCG	GTG	CGC	TTC	TGG	TGT	TCG	CTG	CCT	ACA	GCC	336
201								Arg									
202				100	4		•	-	105	-	4		_	110			
203																	
204	GAC	ACG	TCG	AGC	TTC	GTG	CCC	CTA	GAG	TTG	CGC	GTC	ACA	GCA	GCC	TCC	384
205	Asp	Thr	Ser	Ser	Phe	Val	Pro	Leu	Glu	Leu	Arg	Val	Thr	Ala	Ala	Ser	
	_																

PAGE: 5

RAW SEQUENCE LISTING PATENT APPLICATION US/09/016,159

DATE: 01/27/1999 TIME: 15:14:05

115 120 125 120 125 120 125 120 125 130 130 130 130 130 130 130 130 130 130 130 130 130 130 130 130 135 140 140 140 140 140 130 130 130 135 135 140 140 140 140 140 140 130 131 135 140															IN	PUT S	ET: S	30362.raw
CAC CAC	206			115					120					125				
209	207																	
130	208	GGC	GCT	CCG	CGA	TAT	CAC	CGT	GTC	ATC	CAC	ATC	AAT	GAA	GTA	GTG	CTC	432
212	209	Gly	Ala	Pro	Arg	Tyr	His	Arg	Val	Ile	His	Ile	Asn	Glu	Val	Val	Leu	
212 CTA GAC GCC CCC GTG GGG CTG GTG GGG CGG TTG GCT GAC GAC ACC GGC GLY 145 155 155 155 155 160 155 155 155 160 155 155 160 155 155 160 155 155 160 155 155 160 155 155 160 155 155 160 155 155 160 155 155 160 155 155 160 155 155 160 155 155 160 155 155 160 155 175	210		130					135					140					
14	211																	
150 150 155 160 150 155 160 152 150	212																	480
215	213	Leu	Asp	Ala	Pro	Val	Gly	Leu	Val	Ala	Arg	Leu	Ala	Asp	Glu	Ser	Gly	
216	214	145					150					155					160	
217																		
175																		528
219		His	Val	Val	Leu	_	Trp	Leu	Pro	Pro		Glu	Thr	Pro	Met		Ser	
220						165					170					175		-
Mis		~~ ~		~~~		~~~	~=~	~-~	~=~		~~~	~~~		~~~		~~~		
180 180																		576
223		HIS	тте	Arg	_	GIU	vaı	Asp	vaı		Ата	GIY	Asn	GIY		GIY	ser	
STA CAG AGG AGG GAG ATC CTG GAG GGC CGC ACC GAG TGT GTG CTG AGC G24					180					182					190			
225		CITIZ	C A C	700	CITIC!	C A C	אתוכי	CITIC	C7.C	ccc	aaa	N CC	C2\C	TI CITI	CTTC	CTC	NCC.	624
226																		624
227		Val	GIII	_	val	GIU	116	пеп		GIY	Arg	1111	GIU	-	vaı	пеп	Ser	
AAC				193					200					205				
229		אאר	СТС	CGG	GGC	CGG	ACG	CGC	ጥልሮ	ACC	ጥጥር	CCC	GTC	СТС	aca	ССТ	ΔΤΩ	672
230																		072
231		11011		**** 9	017		****	_	-1-							5		
Secondary Seco																		
233		GCT	GAG	CCG	AGC	TTC	GGC	GGC	TTC	TGG	AGC	GCC	TGG	TCG	GAG	CCT	GTG	720
234																		
236 TCG CTG CTG ACG CCT AGG GAC CTG GAC CTC ACG CTC TCC 768 237 Ser Leu Leu Thr Pro Leu ACC ILeu Thr Leu Ser 255 Ser 270 Ser 280	234						_	•		-			•					
237	235																	
238	236	TCG	CTG	CTG	ACG	CCT	AGC	GAC	CTG	GAC	CCC	CTC	ATC	CTG	ACG	CTC	TCC	768
239 240	237	Ser	Leu	Leu	Thr	Pro	Ser	Asp	Leu	Asp	Pro	Leu	Ile	Leu	Thr	Leu	Ser	
240 CTC ATC CTC GTG GTC ATC CTG GTG CTC ACC GTG CTC GTG CTC S16 241 Leu Ile Leu Val Ile Leu Val Leu Leu Leu ALa Leu Leu Leu ALa Leu Leu <td>238</td> <td></td> <td></td> <td></td> <td></td> <td>245</td> <td></td> <td></td> <td></td> <td></td> <td>250</td> <td></td> <td></td> <td></td> <td></td> <td>255</td> <td></td> <td></td>	238					245					250					255		
241 Leu Ile Leu Val Val Ile Leu Leu Thr Val Leu Ala Leu Leu Ala Leu Leu Ala Leu Leu Ala Leu Ala Leu The The Leu Leu Leu The The Leu Leu Leu Leu The The Leu Leu <td>239</td> <td></td>	239																	
242 243 244 TCC CAC CGC CGG GCT CTG AAG CAG AAG ATC TGG CCT GGC ATC CCG AGC AGC AGC AGC AGC AGC AGC AGC AG	240																	816
243 244 TCC CAC CGC CGG GCT CTG AAG CAG AAG ATC TGG CCT GGC ATC CCG AGC 864 245 Ser His Arg Arg Ala Leu Lys Gln Lys Ile Trp Pro Gly Ile Pro Ser 246 246 275 280 285 247 280 285 248 CCA GAG AGC GAG TTT GAA GGC CTC TTC ACC ACC CAC AAG GGT AAC TTC 912 249 Pro Glu Ser Glu Phe Glu Gly Leu Phe Thr Thr His Lys Gly Asn Phe 290 250 295 300 251 300 252 CAG CTG TGG CTG TAC CAG AAT GAT GGC TGC CTG TGG TGG AGC CCC TGC 960 253 Gln Leu Trp Leu Tyr Gln Asn Asp Gly Cys Leu Trp Trp Ser Pro Cys 310 315 320 254 305 310 315 320 255 ACC CCC TTC ACG GAG GAC CCA CCT GCT TCC CTG GAA GTC CTC TCA GAG 1008 257 Thr Pro Phe Thr Glu Asp Pro Pro Ala Ser Leu Glu Val Leu Ser Glu		Leu	Ile	Leu		Val	Ile	Leu	Val		Leu	Thr	Val	Leu		Leu	Leu	
244 TCC CAC CGG GCT CTG AAG CAG AAG ATG CCT GGC ATC CCG AGC AGC 864 245 Ser His Arg Ala Leu Lys Gln Lys Ile Trp Pro Gly Ile Pro Ser 246 CCA CAG AGC CAG ALC CAC AAG GGT AAC TTC 912 247 CCA GAG AGC GAG TTT GAA GGC CTC TTC ACC ACC AAG GGT AAC TTC 912 249 Pro Glu Ser Glu Phe Glu Gly Leu Phe Thr His Lys Gly AAC TTC 912 250 290 TTT TAC CAG AAT GAT GGC TGC TGG AGC CCC TGC TGG AGC CCC TGG AGC CCC TTG AGC CCT T					260					265					270			
245 Ser His Arg Arg Ala Leu Lys Gln Lys Ile Trp Pro Gly Ile Pro Ser 246 275 280 285 285 285 285 285 247 248 CCA GAG AGC GAG TTT GAA GGC CTC TTC ACC ACC CAC AAG GGT AAC TTC 912 249 Pro Glu Ser Glu Phe Glu Gly Leu Phe Thr Thr His Lys Gly Asn Phe 250 290 295 300 251 300 251 252 CAG CTG TGG CTG TAC CAG AAT GAT GGC TGC CTG TGG TGG AGC CCC TGC 960 960 253 Gln Leu Trp Leu Tyr Gln Asn Asp Gly Cys Leu Trp Trp Ser Pro Cys 315 320 320 320 325 320 320 315 320 320 325 320 325 325 320 325 320 325 320 325 320 320 325 320 320 325 320 320 325 320 320 325 320 320 325 320 320 325 320 325 320 320 320 320 320 320 320 320 320 320 320 320 320 320 320 320						~ ~~												
246 275 280 285 285 247 248 CCA GAG AGC GAG TTT GAA GGC CTC TTC ACC ACC CAC AAG GGT AAC TTC 912 249 Pro Glu Ser Glu Phe Glu Gly Leu Phe Thr Thr His Lys Gly Asn Phe 250 290 295 295 300 300 290 480 Phe Phe Thr Thr His Lys Gly Asn Phe 300 290 295 295 295 300 295																		864
247 248		ser	His		Arg	Ата	Leu	Lys		ьуs	шe	Trp	Pro		TTE	Pro	ser	
248 CCA GAG AGC GAG AGC GAG TTT GAA GGC CTC TTC ACC ACC CAC AAG GGT AAC TTC 912 249 Pro Glu Ser Glu Phe Glu Gly Leu Phe Thr Thr His Lys Gly Asn Phe 290 250 290 295 295 251 300 252 CAG CTG TGG CTG TAC CAG AAT GAT GGC TGC CTG TGG TGG AGC CCC TGC 960 253 Gln Leu Trp Leu Tyr Gln Asn Asp Gly Cys Leu Trp Trp Ser Pro Cys 254 305 310 310 310 255 315 256 ACC CCC TTC ACG GAG GAC CCA CCT GCT TCC CTG GAA GTC CTC TCA GAG 257 Thr Pro Phe Thr Glu Asp Pro Pro Ala Ser Leu Glu Val Leu Ser Glu				275					280					285				
249 Pro Glu Ser Glu Phe Glu Gly Leu Phe Thr Thr His Lys Gly Asn Phe 250 250 290 Ter Glu 295 Ter Thr Thr His Lys Gly Asn Phe 300 251 251 Ter Car Car Car Car Car Car Car Car Car Ca		CCA	C N C	700	a 2 a	mmm	~ A A	cca	ama	mma	7.00	7.00	a a a	220	OOT.	220	mm/C	013
250																		312
251 252		FIO		ser	GIU	PHE	GIU	_	neu	FIIE	1111	TIIL		пуэ	Gry	ASII	FIIE	
252 CAG CTG TGG CTG TAC CAG AAT GAT GGC TGC CTG TGG TGG AGC CCC TGC 960 253 Gln Leu Trp Leu Tyr Gln Asn Asp Gly Cys Leu Trp Trp Ser Pro Cys 254 305 - 310 - 315 - 320 255 256 ACC CCC TTC ACG GAG GAC CCA CCT GCT TCC CTG GAA GTC CTC TCA GAG 1008 257 Thr Pro Phe Thr Glu Asp Pro Pro Ala Ser Leu Glu Val Leu Ser Glu			230					293					300					
253 Gln Leu Trp Leu Tyr Gln Asn Asp Gly Cys Leu Trp Trp Ser Pro Cys 254 305 310 310 315 320 255 256 ACC CCC TTC ACG GAG GAC CCA CCT GCT TCC CTG GAA GTC CTC TCA GAG 1008 257 Thr Pro Phe Thr Glu Asp Pro Pro Ala Ser Leu Glu Val Leu Ser Glu		CAG	СТС	тсс	СТС	тас	CAG	א מ	СДТ	GGC	TCC	СТС	тсс	тсс	AGC	כככ	тсс	960
254 305 310 315 320 255 256 ACC CCC TTC ACG GAG GAC CCA CCT GCT TCC CTG GAA GTC CTC TCA GAG 1008 257 Thr Pro Phe Thr Glu Asp Pro Pro Ala Ser Leu Glu Val Leu Ser Glu																		700
255 256 ACC CCC TTC ACG GAG GAC CCA CCT GCT TCC CTG GAA GTC CTC TCA GAG 257 Thr Pro Phe Thr Glu Asp Pro Pro Ala Ser Leu Glu Val Leu Ser Glu			 u	1		-1-				1	~ <u> </u>		1	1			_	
ACC CCC TTC ACG GAG GAC CCA CCT GCT TCC CTG GAA GTC CTC TCA GAG Thr Pro Phe Thr Glu Asp Pro Pro Ala Ser Leu Glu Val Leu Ser Glu																		
257 Thr Pro Phe Thr Glu Asp Pro Pro Ala Ser Leu Glu Val Leu Ser Glu		ACC	CCC	TTC	ACG	GAG	GAC	CCA	CCT	GCT	TCC	CTG	GAA	GTC	CTC	TCA	GAG	1008
-																		
							_											

PAGE: 1

SEQUENCE VERIFICATION REPORT PATENT APPLICATION US/09/016,159

DATE: 01/27/1999 TIME: 15:14:06

INPUT SET: S30362.raw

Line Error

Original Text

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. §§ 1.821-1.825 for the following reason(s):

- [] 1. This application clearly fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990, and at 55 FR 18230, May 1, 1990.
- [X] 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. § 1.821(c).
- [X] 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. § 1.821(e).
- 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. §§ 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing".
- [] 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 C.F.R. § 1.825(d).
- [] 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. § 1.821(e).
- [X] 7. Other:

m 1 " *

A paper copy sequence listing was filed with the application. However, no computer-readable copy or request that the Office prepare such copy from the listing filed in the parent application (37 C.F.R. § 1.821(e)) was received. Additionally, no amendment directing entry of the sequence listing into the specification was submitted.

Applicant must provide:

- [X] An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- [X] An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry of the sequence listing into the specification.
- [X] A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. § 1.821(e) or § 1.821(f) or § 1.821(g) or § 1.825(b) or § 1.825(d).

For questions regarding compliance with these requirements, please contact one of the following:

For rules interpretation, call (703) 308-4216.

For CRF submission help, call (703) 308-4212.

For PatentIn software help, call (703) 557-0400.

Please return a copy of this notice with your response.